The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
ApexOnco Front Page
Recent articles
What could be the four HengRui assets picked up by Bristol?
The conjugates SYS6005 and TQB2101 feature among first-in-human study entrants.
Minghui’s MHB088C will soon start phase 3 in China.
After earlier masked probody setbacks, CytomX surprises with CX-2051.
Imfinzi hits on disease-free survival, but BCG won't be displaced.
The group’s latest update focused on new data with the KRAS G12C inhibitor elironrasib.
TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.